

Resource Summary Report

Generated by [NIF](#) on Sep 11, 2026

OVCAR-3

RRID:CVCL_0465

Type: Cell Line

Proper Citation

RRID:CVCL_0465

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0465

Proper Citation: RRID:CVCL_0465

Description: Cell line OVCAR-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:1348364](#), [PMID:1892748](#), [PMID:2041050](#), [PMID:2307530](#), [PMID:2653399](#), [PMID:3335022](#), [PMID:3930572](#), [PMID:6372095](#), [PMID:6385258](#), [PMID:6604576](#), [PMID:8557231](#), [PMID:9041185](#), [PMID:9331090](#), [PMID:9698466](#), [PMID:10700174](#), [PMID:11414198](#), [PMID:11793438](#), [PMID:12417041](#), [PMID:12960427](#), [PMID:15748285](#), [PMID:16382445](#), [PMID:17088437](#), [PMID:18277095](#), [PMID:18560578](#), [PMID:19372543](#), [PMID:19926575](#), [PMID:20164919](#), [PMID:20204287](#), [PMID:20215515](#), [PMID:21912889](#), [PMID:22068913](#), [PMID:22328975](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:22628656](#), [PMID:22710073](#), [PMID:23172893](#), [PMID:23351415](#), [PMID:23415752](#), [PMID:23839242](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24023729](#), [PMID:24279929](#), [PMID:24434149](#), [PMID:24670534](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26169745](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27235858](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:27807467](#), [PMID:28100988](#), [PMID:28196595](#), [PMID:28273451](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:32612269](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AKT genetic alteration cell panel (ATCC TCP-1029).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OVCAR-3

Synonyms: OvcAR-3, OVCAR 3, OVCAR.3, NIH:OVCAR-3, NIH:OvcAR-3, NIH:OVCAR3, NIH-OVCAR-3, NIH:OVCAR3, OVCAR3, OvcAR3

Cross References: BTO:BTO_0000812, CLO:CLO_0008171, CLO:CLO_0008279, CLO:CLO_0051451, EFO:EFO_0003061, MCCL:MCC:0000363, CLDB:cl3712, CLDB:cl3780, CLDB:cl5237, Abcam:ab275471, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-161, BCRC:60551, BCRJ:0317, BioGRID_ORCS_Cell_line:981, BioSample:SAMN01821585, BioSample:SAMN03471390, BioSample:SAMN05292457, BioSample:SAMN10987888, cancercellines:CVCL_0465, CCRID:1101HUM-PUMC000362, CCRID:3101HUMTCHu228, CCRID:4201HUM-CCTCC00119, CCTCC:GDC0119, Cell_Model_Passport:SIDM00105, ChEMBL-Cells:ChEMBL3307564, ChEMBL-Targets:ChEMBL614213, CLS:300307, Cosmic:687926, Cosmic:688104, Cosmic:755845, Cosmic:809113, Cosmic:844347, Cosmic:845142, Cosmic:875859, Cosmic:897433, Cosmic:905933, Cosmic:906577, Cosmic:920357, Cosmic:924144, Cosmic:927564, Cosmic:949227, Cosmic:974296, Cosmic:991321, Cosmic:1044239, Cosmic:1092623, Cosmic:1093553, Cosmic:1102816, Cosmic:1139222, Cosmic:1175883, Cosmic:1218877, Cosmic:1305312, Cosmic:1312192, Cosmic:1312354, Cosmic:1436033, Cosmic:1482525, Cosmic:1524357, Cosmic:1709250, Cosmic:1998465, Cosmic:2186584, Cosmic-CLP:905933, DepMap:ACH-000001, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS419ENC, GDSC:905933, GEO:GSM2122, GEO:GSM50219, GEO:GSM50282, GEO:GSM95463, GEO:GSM185135, GEO:GSM185136, GEO:GSM274703, GEO:GSM313683, GEO:GSM459733, GEO:GSM459741, GEO:GSM645843, GEO:GSM659393, GEO:GSM711708, GEO:GSM743474, GEO:GSM743498, GEO:GSM750817, GEO:GSM784564, GEO:GSM799362, GEO:GSM799363, GEO:GSM799425, GEO:GSM799426, GEO:GSM844668, GEO:GSM847106, GEO:GSM851934, GEO:GSM887456, GEO:GSM888536, GEO:GSM1001493, GEO:GSM1153434, GEO:GSM1153435, GEO:GSM1178508, GEO:GSM1178509, GEO:GSM1181276, GEO:GSM1181278, GEO:GSM1186813, GEO:GSM1186814, GEO:GSM1186815, GEO:GSM1186816, GEO:GSM1186827, GEO:GSM1291149, GEO:GSM1374771, GEO:GSM1374772, GEO:GSM1374773, GEO:GSM1670317, GEO:GSM2124645, GEO:GSM2474989, IARC_TP53:1417, ICLC:HTL97004, IGRhCellID:OVCAR3, IZSLER:BS TCL 131, KCB:KCB 2006106YJ, KCLB:30161, LiGeA:CCLE_502, LINCS_LDP:LCL-1522, Lonza:31, MetaboLights:MTBLS150, MetaboLights:MTBLS152, Millipore:SCC257, NCBI_Iran:C430, NCI-DTP:OVCAR-3, PharmacDB:OVCAR3_1217_2019, PRIDE:PXD003105, PRIDE:PXD003539, PRIDE:PXD003668, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_0465, PubChem_Cell_line:CVCL_0465, RCB:RCB2135, SKY/M-FISH/CGH:2742, TKG:TKG 0602, TOKU-E:2754, Ubigen:YC-D019, Wikidata:Q54937005

ID: CVCL_0465

Record Creation Time: 20220427T221403+0000

Ratings and Alerts

No rating or validation information has been found for OVCAR-3.

Warning: Discontinued: ICLC; HTL97004

Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AKT genetic alteration cell panel (ATCC TCP-1029).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1642 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Bai Y, et al. (2026) Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase. Cancer discovery, 16(1), 135.

Mohiuddin TM, et al. (2026) Synthetic zipper mediated pre-targeting system for near-infrared photoimmunotherapy. iScience, 29(2), 114558.

Kimura N, et al. (2026) CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. Cancer research communications, 6(2), 383.

Zhang J, et al. (2026) Gemcitabine activates the Hippo signaling pathway and suppresses tumor growth by stabilizing large tumor suppressor kinase 2 through the hypoxia-inducible factor 1-alpha/ubiquitin protein ligase E3 component N-recognin 5 axis. Journal of cell communication and signaling, 20(2), e70085.

Santander GN, et al. (2026) Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. Cell reports methods, 101515.

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. Molecular cancer therapeutics.

Uno K, et al. (2026) Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation. Science advances, 12(6), eadu5944.

Saleh A, et al. (2026) CCDC80 suppresses high-grade serous ovarian cancer migration via negative regulation of B7-H3. *Molecular oncology*.

Guo X, et al. (2026) The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. *iScience*, 29(7), 116390.

Wilms G, et al. (2026) The protein kinase DYRK1B is a p53 target gene and functions as a negative feedback regulator of the transcription factor RFX7. *Cell death & disease*, 17(1).

Meng H, et al. (2026) Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. *Science advances*, 12(16), eaeb0855.

Zhang Z, et al. (2026) A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. *Pharmaceuticals (Basel, Switzerland)*, 19(4).

Li T, et al. (2026) Overexpression of SLC44A4 suppresses ferroptosis and reduces lipid peroxidation via noncanonical NF- κ B signaling in a NIK-dependent manner. *Annals of medicine*, 58(1), 2677931.

Vuong TT, et al. (2026) DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment. *Cancer research communications*, 6(7), 1721.

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. *Molecular oncology*.

Oelgarth N, et al. (2026) Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity. *Journal for immunotherapy of cancer*, 14(7).

Scholler J, et al. (2026) Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer. *Frontiers in immunology*, 17, 1805950.

Gjerde CH, et al. (2026) A 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy response. *EBioMedicine*, 124, 106135.

Zeng B, et al. (2026) HE4 drives PD-L1 expression in myeloid cells via IFN- γ -JAK-STAT3 signaling to promote tumor immune evasion. *Cell reports. Medicine*, 7(4), 102691.

Hua T, et al. (2026) Salidroside represses ovarian cancer progression by targeting FSP1-dependent ferroptosis. *Journal of ovarian research*, 19(1).